Developer docs
API playgroundTry for free, no card

Search company profiles

BiovelocITA

Full company profile

uuid0003lp2

Namestring
BiovelocITA
Legal namestring
BiovelocITA S.r.l.
Websiteurl
biovelocita.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

BiovelocITA S.r.l. is Italy's first biotech accelerator, founded in 2015 in Milan by serial biotech entrepreneurs Silvano Spinelli (Chairman) and Gabriella Camboni (CEO), alongside Sofinnova Partners as a founding partner. The company identifies promising early-stage Italian scientific research projects and provides capital plus strategic and management expertise to transform them into operational biotech companies, with a focus on red biotech therapeutic areas including oncology, rare genetic diseases, diabetes, infectious diseases, and amyloidosis. Its portfolio includes three operating companies (Enthera Pharmaceuticals in diabetes/gastroenterology, Alia Therapeutics in CRISPR/Cas9 gene editing, and Amypopharma in nanoparticle-based amyloidosis therapy) plus additional research projects in collaboration with leading Italian institutions such as IFOM, Ospedale San Raffaele, Istituto Superiore di Sanità, CIBIO at the Università di Trento, Università Milano-Bicocca, and Università Magna Graecia di Catanzaro.

The company's business model is equity investment rather than fee-for-service: BiovelocITA deploys capital into selected startups and research projects in exchange for equity stakes, with returns generated through portfolio company exits via M&A or public offerings. The company has raised over 14 million euros across two capital increases (7 million euros in 2016 and 7.245 million euros in 2017) from founders, Atlante Seed (Intesa Sanpaolo group), and private investors coordinated by BANOR SIM and Banca Profilo. Go-to-market relies on proactive scouting of university research, exclusive partnerships with Italian research institutions, and the founders' proven track record of building and exiting biotech companies (EOS sold to Clovis Oncology for 470 million dollars in 2013, Novuspharma IPO in 2000). Distribution operates through a direct investment model, with TTFactor providing structured technology transfer pathways to commercial licensing.

Notable portfolio achievements include Enthera's 28 million euro Series A round in 2019 to advance type 1 diabetes and inflammatory bowel disease therapies, Alia Therapeutics' position as Italy's first company active in treating genetic diseases with genome editing, and Amypopharma's two granted patents in nanoparticle amyloidosis therapy. The company maintains a lean team of 1-10 employees and concentrates exclusively on the Italian market, leveraging Sofinnova's international VC network and the founders' relationships with international pharma acquirers to support portfolio exits.

Short descriptiontext

BiovelocITA is Italy's first biotech accelerator, founded in 2015, that invests capital and provides strategic management to transform early-stage Italian life sciences research into operational biotech companies across oncology, gene editing, diabetes, and rare diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMilan, Italy
HQ citystring
Milan
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biotech accelerator, life sciences investment, red biotech ventures, early stage biotech, therapeutic research funding
Industry5 codes
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYEDAHAGAI
Biomedical Sciences & Medical Research Institutes (University-Based)
Education/Higher Education (Colleges & Universities)/Medical & Health Sciences Universities
SECONDARYHLAGAJAN
Knowledge Management & Scientific Collaboration / Literature Intelligence
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
NAICS code4 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)541715
  • Portfolio Management and Investment Advice523940
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
  • Investment Advice6282
Product category
Biotech Accelerator and Investment Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Equity Investment Returns
TypeLicensing Royalties
Description

BiovelocITA invests capital in biotech startups in exchange for equity stakes. Returns are generated through portfolio company exits via M&A or public offerings. The company was founded by serial biotech entrepreneurs (Spinelli and Camboni) who previously sold EOS to Clovis Oncology for $470 million and built Novuspharma through to acquisition.

biovelocita.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

BiovelocITA is Italy's first biotech accelerator that identifies, funds, and supports the development of promising life sciences research projects into operational biotech companies. It provides seed capital, strategic management expertise, and operational guidance to bridge Italian academic research from laboratory discovery through proof-of-concept and into clinical development, taking equity stakes in portfolio companies spanning gene editing, diabetes therapy, amyloidosis treatment, oncology, and infectious disease vaccines.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • EOS (previous company by founders) was acquired by Clovis Oncology in November 2013 for $470 million
+2 more records
Product overview1 text field

BiovelocITA is the first Italian biotech accelerator that identifies, funds, and supports the development of promising life sciences research projects into successful biotech companies. Rather than offering a single product or platform, BiovelocITA operates a portfolio of startup companies and research projects across multiple therapeutic areas including oncology, diabetes, infectious diseases, amyloidosis, and gene editing. The accelerator provides capital and strategic-management expertise to transform laboratory discoveries into operational industrial ventures, with notable portfolio companies including Enthera Pharmaceuticals (diabetes therapy), Alia Therapeutics (CRISPR gene editing), and Amypopharma (amyloidosis treatment), alongside collaborative research projects with institutions such as Istituto Superiore di Sanità, Università Magna Graecia, and IFOM.

Product and service4 records
1Biotech Acceleration Program
CategoryBiotech Accelerator Services
Description

End-to-end accelerator service for Italian biotech research projects, providing seed capital, strategic management, operational support, and proof-of-concept development through to clinical phases. Intended for Italian academic spin-offs and biotech startups developing red biotech therapeutics.

2Enthera Pharmaceuticals (Portfolio Company)
CategoryPortfolio Company Investment
Description

Portfolio company founded in collaboration with Ospedale San Raffaele focused on developing therapies for type 1 diabetes and inflammatory bowel diseases. Enthera raised €28 million in Series A funding.

3Alia Therapeutics (Portfolio Company)
CategoryPortfolio Company Investment
Description

Italy's first company dedicated to treating genetic diseases using CRISPR/Cas9 gene editing technologies, developing evoCas9 precision molecular scissors for therapeutic applications. Spin-off of CIBIO at the University of Trento.

4Amypopharma (Portfolio Company)
CategoryPortfolio Company Investment
Description

Spin-off of Università Milano-Bicocca developing nanoparticles for amyloidosis therapy, focusing on protein fibril accumulation diseases including Alzheimer's. Based on research by Professor Massimo Masserini and Dr. Francesca Re with 60+ publications and two granted patents.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1Istituto Superiore di Sanità (ISS)
Strategic tierCore Research PartnerTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Italy's leading public health research institute. BiovelocITA collaborates with Dr. Maurizio Federico's team to develop innovative therapeutic vaccine platform against cancer and chronic infectious diseases using extracellular vesicle technology.

biovelocita.com
Strategic tierResearch PartnerTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

BiovelocITA supports Professor Pierfrancesco Tassone's project developing targeted antibody therapy against CD43 protein for treatment of childhood and adult leukemia.

3Università Milano Bicocca
Strategic tierSpin-Off PartnerTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

BiovelocITA holds a stake in Amypopharma, a spin-off developing nanoparticles for amyloidosis therapy based on research by Professor Massimo Masserini and Dr. Francesca Re with 60+ publications and two granted patents.

biovelocita.com
Strategic tierCore Research PartnerTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Dipartimento di Biologia Cellulare, Computazionale e Integrata. Home to Anna Cereseto's laboratory that developed evoCas9 precision gene editing technology. CIBIO spin-off Alia Therapeutics is BiovelocITA's portfolio company.

Strategic tierCore PartnerTypeStrategic or Co-development PartnerAnnounced on2016-01-01
Description

Technology transfer company founded by IFOM and IEO that negotiates licensing agreements for commercial rights. At project conclusion, exclusive commercial licenses will be conferred to IFOM/BiovelocITA co-participated spin-offs.

Strategic tierCore Research PartnerTypeStrategic or Co-development PartnerAnnounced on2016-01-01
Description

International excellence in molecular oncology research. BiovelocITA collaborates with IFOM's Dr. Fabrizio d'Adda di Fagagna on DNA damage signaling and repair mechanisms for novel cancer therapeutics, with potential applications in aging-related diseases.

7Ospedale San Raffaele
Strategic tierCore Research PartnerTypeStrategic or Co-development PartnerAnnounced on2016-01-01
Description

Leading Milan research hospital. BiovelocITA co-founded Enthera with Professor Paolo Fiorina to develop therapies targeting IGFBP3 hormone role in diabetic enteropathy and diabetes complications.

biovelocita.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Leading European life-sciences VC (€1.3B+ AUM) that is also BiovelocITA's founding partner. Overlaps directly as a biotech investor in European therapeutic assets, but operates at far greater scale and geographic breadth.

TypeDirect peer
Description

Dutch biotech seed/early-stage VC that builds companies from academic science in similar therapeutic areas (oncology, rare disease) — a directly comparable European academic-translation platform.

TypeBroad incumbent
Description

Pan-European biotech investor with funds backing early-to-growth therapeutic platforms; competes with BiovelocITA for European academic spin-out deals and Series A follow-on participation.

TypeDirect peer
Description

US-/UK-based biotech-focused VC that forms, finances, and builds companies from academic science across modalities (gene editing, cell therapy, RNA) — a closely comparable accelerator-style model.

TypeDirect peer
Description

European life-sciences VC focused on early-stage asset-centric investing from academic origins — directly analogous model of translating European academic discoveries into biotech companies.

TypeBroad incumbent
Description

Israel-based biotech VC investing in therapeutic companies from early to clinical stage; overlaps in modality and stage of investment but operates outside Italy.

TypeBroad incumbent
Description

European healthcare/life-sciences investor providing early-to-growth equity to biotech companies — comparable in stage and therapeutic focus but with significantly larger AUM.

TypeDirect peer
Description

Swiss biotech VC financing early-stage therapeutic companies emerging from European academic research — a directly comparable European academic-translation platform.

TypeRegional player
Description

Italian business angel network that co-invests in Italian early-stage ventures including biotech — competes for and co-invests in the same Italian academic spin-off deal flow.

TypeOthers
Description

Italian banking group whose venture arm (Atlante Seed, managed by Indaco SGR) is a BiovelocITA investor — relevant ecosystem participant providing capital but also a potential allocator of competing accelerator/incubator vehicles.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BiovelocITA

Biotech Accelerator and Investment Servicesbiovelocita.com

BiovelocITA is Italy's first biotech accelerator, founded in 2015, that invests capital and provides strategic management to transform early-stage Italian life sciences research into operational biotech companies across oncology, gene editing, diabetes, and rare diseases.

What BiovelocITA does

BiovelocITA S.r.l. is Italy's first biotech accelerator, founded in 2015 in Milan by serial biotech entrepreneurs Silvano Spinelli (Chairman) and Gabriella Camboni (CEO), alongside Sofinnova Partners as a founding partner. The company identifies promising early-stage Italian scientific research projects and provides capital plus strategic and management expertise to transform them into operational biotech companies, with a focus on red biotech therapeutic areas including oncology, rare genetic diseases, diabetes, infectious diseases, and amyloidosis. Its portfolio includes three operating companies (Enthera Pharmaceuticals in diabetes/gastroenterology, Alia Therapeutics in CRISPR/Cas9 gene editing, and Amypopharma in nanoparticle-based amyloidosis therapy) plus additional research projects in collaboration with leading Italian institutions such as IFOM, Ospedale San Raffaele, Istituto Superiore di Sanità, CIBIO at the Università di Trento, Università Milano-Bicocca, and Università Magna Graecia di Catanzaro.

The company's business model is equity investment rather than fee-for-service: BiovelocITA deploys capital into selected startups and research projects in exchange for equity stakes, with returns generated through portfolio company exits via M&A or public offerings. The company has raised over 14 million euros across two capital increases (7 million euros in 2016 and 7.245 million euros in 2017) from founders, Atlante Seed (Intesa Sanpaolo group), and private investors coordinated by BANOR SIM and Banca Profilo. Go-to-market relies on proactive scouting of university research, exclusive partnerships with Italian research institutions, and the founders' proven track record of building and exiting biotech companies (EOS sold to Clovis Oncology for 470 million dollars in 2013, Novuspharma IPO in 2000). Distribution operates through a direct investment model, with TTFactor providing structured technology transfer pathways to commercial licensing.

Notable portfolio achievements include Enthera's 28 million euro Series A round in 2019 to advance type 1 diabetes and inflammatory bowel disease therapies, Alia Therapeutics' position as Italy's first company active in treating genetic diseases with genome editing, and Amypopharma's two granted patents in nanoparticle amyloidosis therapy. The company maintains a lean team of 1-10 employees and concentrates exclusively on the Italian market, leveraging Sofinnova's international VC network and the founders' relationships with international pharma acquirers to support portfolio exits.

BiovelocITA firmographics

Firmographics
Name
BiovelocITA
Legal name
BiovelocITA S.r.l.
Website
https://biovelocita.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
BiovelocITA is Italy's first biotech accelerator, founded in 2015, that invests capital and provides strategic management to transform early-stage Italian life sciences research into operational biotech companies across oncology, gene editing, diabetes, and rare diseases.
Ownership category
akta.pro rank

BiovelocITA industry classification

Industry
Product category
Biotech Accelerator and Investment Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715), Portfolio Management and Investment Advice (523940)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836), Investment Advice (6282)
akta.pro industry
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYEDAHAGAI
Biomedical Sciences & Medical Research Institutes (University-Based)
Education/Higher Education (Colleges & Universities)/Medical & Health Sciences Universities
SECONDARYHLAGAJAN
Knowledge Management & Scientific Collaboration / Literature Intelligence
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking

Keywords

  • Biotech accelerator
  • Life sciences investment
  • Red biotech ventures
  • Early stage biotech
  • Therapeutic research funding

Where BiovelocITA is headquartered

Location

Headquarters

HQ city
Milan
HQ country
Italy
HQ region
Europe

Offices1 record

Markets served

BiovelocITA business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Equity Investment Returns: BiovelocITA invests capital in biotech startups in exchange for equity stakes. Returns are generated through portfolio company exits via M&A or public offerings. The company was founded by serial biotech entrepreneurs (Spinelli and Camboni) who previously sold EOS to Clovis Oncology for $470 million and built Novuspharma through to acquisition.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

BiovelocITA product offering

Product offering

Core offering

BiovelocITA is Italy's first biotech accelerator that identifies, funds, and supports the development of promising life sciences research projects into operational biotech companies. It provides seed capital, strategic management expertise, and operational guidance to bridge Italian academic research from laboratory discovery through proof-of-concept and into clinical development, taking equity stakes in portfolio companies spanning gene editing, diabetes therapy, amyloidosis treatment, oncology, and infectious disease vaccines.

Product overview

BiovelocITA is the first Italian biotech accelerator that identifies, funds, and supports the development of promising life sciences research projects into successful biotech companies. Rather than offering a single product or platform, BiovelocITA operates a portfolio of startup companies and research projects across multiple therapeutic areas including oncology, diabetes, infectious diseases, amyloidosis, and gene editing. The accelerator provides capital and strategic-management expertise to transform laboratory discoveries into operational industrial ventures, with notable portfolio companies including Enthera Pharmaceuticals (diabetes therapy), Alia Therapeutics (CRISPR gene editing), and Amypopharma (amyloidosis treatment), alongside collaborative research projects with institutions such as Istituto Superiore di Sanità, Università Magna Graecia, and IFOM.

Differentiator

Problem solved

Functional benefit

Products and services

  • Biotech Acceleration Program End-to-end accelerator service for Italian biotech research projects, providing seed capital, strategic management, operational support, and proof-of-concept development through to clinical phases. Intended for Italian academic spin-offs and biotech startups developing red biotech therapeutics.
  • Enthera Pharmaceuticals (Portfolio Company) Portfolio company founded in collaboration with Ospedale San Raffaele focused on developing therapies for type 1 diabetes and inflammatory bowel diseases. Enthera raised €28 million in Series A funding.
  • Alia Therapeutics (Portfolio Company) Italy's first company dedicated to treating genetic diseases using CRISPR/Cas9 gene editing technologies, developing evoCas9 precision molecular scissors for therapeutic applications. Spin-off of CIBIO at the University of Trento.
  • Amypopharma (Portfolio Company) Spin-off of Università Milano-Bicocca developing nanoparticles for amyloidosis therapy, focusing on protein fibril accumulation diseases including Alzheimer's. Based on research by Professor Massimo Masserini and Dr. Francesca Re with 60+ publications and two granted patents.

Quantifiable outcome

  • EOS (previous company by founders) was acquired by Clovis Oncology in November 2013 for $470 million
  • +2 more outcomes

Companies that use BiovelocITA

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles2 records

BiovelocITA technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

BiovelocITA partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core research partner, research partner, spin-off partner and core partner.

  • Istituto Superiore di Sanità (ISS)core research partnerStrategic or Co-development Partner · 1 January 2019Italy's leading public health research institute. BiovelocITA collaborates with Dr. Maurizio Federico's team to develop innovative therapeutic vaccine platform against cancer and chronic infectious diseases using extracellular vesicle technology.
  • Università Magna Graecia di Catanzaroresearch partnerStrategic or Co-development Partner · 1 January 2019BiovelocITA supports Professor Pierfrancesco Tassone's project developing targeted antibody therapy against CD43 protein for treatment of childhood and adult leukemia.
  • Università Milano Bicoccaspin-off partnerStrategic or Co-development Partner · 1 January 2019BiovelocITA holds a stake in Amypopharma, a spin-off developing nanoparticles for amyloidosis therapy based on research by Professor Massimo Masserini and Dr. Francesca Re with 60+ publications and two granted patents.
  • CIBIO (Università di Trento)core research partnerStrategic or Co-development Partner · 1 January 2019Dipartimento di Biologia Cellulare, Computazionale e Integrata. Home to Anna Cereseto's laboratory that developed evoCas9 precision gene editing technology. CIBIO spin-off Alia Therapeutics is BiovelocITA's portfolio company.
  • TTFactor (IFOM/IEO Technology Transfer)core partnerStrategic or Co-development Partner · 1 January 2016Technology transfer company founded by IFOM and IEO that negotiates licensing agreements for commercial rights. At project conclusion, exclusive commercial licenses will be conferred to IFOM/BiovelocITA co-participated spin-offs.
  • IFOM (Istituto FIRC di Oncologia Molecolare)core research partnerStrategic or Co-development Partner · 1 January 2016International excellence in molecular oncology research. BiovelocITA collaborates with IFOM's Dr. Fabrizio d'Adda di Fagagna on DNA damage signaling and repair mechanisms for novel cancer therapeutics, with potential applications in aging-related diseases.
  • Ospedale San Raffaelecore research partnerStrategic or Co-development Partner · 1 January 2016Leading Milan research hospital. BiovelocITA co-founded Enthera with Professor Paolo Fiorina to develop therapies targeting IGFBP3 hormone role in diabetic enteropathy and diabetes complications.

Scale indicators3 records

Recent moves8 records

Expansion highlights5 records

BiovelocITA competitors and assessment

Company assessment

Broad incumbents

  • Sofinnova Partners: Leading European life-sciences VC (€1.3B+ AUM) that is also BiovelocITA's founding partner. Overlaps directly as a biotech investor in European therapeutic assets, but operates at far greater scale and geographic breadth.
  • Forbion: Pan-European biotech investor with funds backing early-to-growth therapeutic platforms; competes with BiovelocITA for European academic spin-out deals and Series A follow-on participation.
  • Pontifax Venture Capital: Israel-based biotech VC investing in therapeutic companies from early to clinical stage; overlaps in modality and stage of investment but operates outside Italy.
  • TVM Capital Life Science: European healthcare/life-sciences investor providing early-to-growth equity to biotech companies — comparable in stage and therapeutic focus but with significantly larger AUM.

Direct peers

  • BioGeneration Ventures: Dutch biotech seed/early-stage VC that builds companies from academic science in similar therapeutic areas (oncology, rare disease) — a directly comparable European academic-translation platform.
  • Atlas Venture: US-/UK-based biotech-focused VC that forms, finances, and builds companies from academic science across modalities (gene editing, cell therapy, RNA) — a closely comparable accelerator-style model.
  • Medicxi: European life-sciences VC focused on early-stage asset-centric investing from academic origins — directly analogous model of translating European academic discoveries into biotech companies.
  • BioMedPartners: Swiss biotech VC financing early-stage therapeutic companies emerging from European academic research — a directly comparable European academic-translation platform.

Regional players

  • Italian Angels for Growth: Italian business angel network that co-invests in Italian early-stage ventures including biotech — competes for and co-invests in the same Italian academic spin-off deal flow.

Others

  • Intesa Sanpaolo (via Indaco SGR / Atlante Seed): Italian banking group whose venture arm (Atlante Seed, managed by Indaco SGR) is a BiovelocITA investor — relevant ecosystem participant providing capital but also a potential allocator of competing accelerator/incubator vehicles.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

BiovelocITA social profiles

Digital presence

BiovelocITA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BiovelocITA leadership team

Management profile

Number of profiles

Profiles5 records

BiovelocITA subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

BiovelocITA funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BiovelocITA M&A and investment

M&A and investment

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BiovelocITA

What does BiovelocITA do?

BiovelocITA is Italy's first biotech accelerator that identifies, funds, and supports the development of promising life sciences research projects into operational biotech companies. It provides seed capital, strategic management expertise, and operational guidance to bridge Italian academic research from laboratory discovery through proof-of-concept and into clinical development, taking equity stakes in portfolio companies spanning gene editing, diabetes therapy, amyloidosis treatment, oncology, and infectious disease vaccines.

Is BiovelocITA a public or private company?

BiovelocITA is a private company. It is classified as venture growth investor backed and is currently operating.

When was BiovelocITA founded?

BiovelocITA was founded in 2015. It employs 1 to 10 people.

Where is BiovelocITA based?

BiovelocITA is headquartered in Milan, Italy, in the Europe region.

How does BiovelocITA make money?

One revenue line is on record: equity Investment Returns.

Who are BiovelocITA's main competitors?

Broad incumbents on record are Sofinnova Partners, Forbion, Pontifax Venture Capital and TVM Capital Life Science. Direct peers are BioGeneration Ventures, Atlas Venture, Medicxi and BioMedPartners. Italian Angels for Growth is listed as a regional player. Intesa Sanpaolo (via Indaco SGR / Atlante Seed) is listed as an others.

Does BiovelocITA have an API?

No public API is recorded for BiovelocITA.

What industry is BiovelocITA in?

BiovelocITA's product category is Biotech Accelerator and Investment Services. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BebeezItaly’s angels & incubators, venture capital and fintech weekly roundup. News from Consob, AcomeA, Friendz, BiovelocITA, Traipler.com, Locare, Mindesk, Cloudcare – BeBeez InternationalThis weekly roundup covers nine distinct developments in Italy's venture capital, fintech, and startup ecosystem, ranging from regulatory developments to funding rounds and acquisitions. Consob, Italy's market regulator, released a consultation document on ICO and crypto asset regulation, proposing a framework distinct from traditional financial products, with crowdfunding portals as potential intermediaries. Notable transactions include Friendz acquiring a minority stake in video microinfluencer startup Vidoser, BiovelocITA investing €1.9 million in cancer vaccines and leukemia drug development, Mindesk raising $900,000 for its VR CAD interface, and Cloud Care acquiring UK-based insurance comparator Quale.it.FinSMEsBiovelocITA Receives €800K Investment from Atlante SeedBiovelocITA, a Milan-based biotech accelerator, received an €800k investment from Atlante Seed, which took a 10% stake. The accelerator, founded by Silvano Spinelli and Gabriella Camboni, aims to support biotech companies and has secured an initial endowment of about €6m.FinSMEsBiovelocITA Launches to Accelerate Biotech Companies in ItalySofinnova Partners launched BiovelocITA, Italy's first biotech accelerator, with €6m in funding. The accelerator, co-founded by Silvano Spinelli and Gabriella Camboni, has signed a strategic partnership with TTFactor, which manages IP from three Italian research institutes. Over ten biotech projects are under study.